Neuroendocrine activation as a target of modern chronic heart failure pharmacotherapy

Acta Poloniae Pharmaceutica - Drug Research

Volumn 68, Issue 3, 2011, Pages 307-316

  Dobrek, Łukasz ^a   Thor, Piotr ^a  

^a JAGIELLONIAN UNIVERSITY   (Poland)

Author keywords

Anticytokine therapy; Chronic heart failure pharmacotherapy; Endothelin receptor antagonists (ERA); Vasopeptidase inhibitors (VPI); Vasopressin receptor antagonists (VRA)

Indexed keywords

AMBRISENTAN; ATRASENTAN; ATRIAL NATRIURETIC FACTOR; BOSENTAN; BRAIN NATRIURETIC PEPTIDE; CANDOXARTIL; CLAZOSENTAN; CONIVAPTAN; DARUSENTAN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENDOTHELIN RECEPTOR ANTAGONIST; EPLERENONE; ETANERCEPT; FASIDOTRIL; GEMOPATRILAT; INFLIXIMAB; LIXIVAPTAN; MOZAVAPTAN; NESIRITIDE; OMAPATRILAT; PIVLAZ; RECOMBINANT BRAIN DERIVED NEUROTROPHIC FACTOR; RELCOVAPTAN; SAMPATRILAT; SATAVAPTAN; SITAXSENTAN; SPIRONOLACTONE; TEZOSENTAN; TOLVAPTAN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASOPEPTIDASE INHIBITOR; VASOPRESSIN RECEPTOR ANTAGONIST;

ACUTE HEART FAILURE; ADRENERGIC SYSTEM; ANEMIA; ANGIONEUROTIC EDEMA; ASCITES; CHRONOTROPISM; CONFUSION; CORONARY ARTERY DISEASE; COUGHING; CRANIOFACIAL MALFORMATION; DIURESIS; DIZZINESS; DYSMENORRHEA; DYSPNEA; FATIGUE; HEADACHE; HEART DISEASE; HEART FAILURE; HEART HYPERTROPHY; HEART LEFT VENTRICLE OVERLOAD; HEART MUSCLE FIBROSIS; HEART OUTPUT; HEART VENTRICLE HYPERTROPHY; HEPATOSPLENOMEGALY; HUMAN; HYPERTENSION; HYPONATREMIA; INOTROPISM; KIDNEY POLYCYSTIC DISEASE; LIVER TOXICITY; LUNG EDEMA; MUSCLE CELL; NATRIURESIS; NAUSEA; NEUROENDOCRINE SYSTEM; PATENT DUCTUS ARTERIOSUS; PATHOPHYSIOLOGY; PERIPHERAL EDEMA; PREMATURE LABOR; PROSTATE CANCER; PULMONARY HYPERTENSION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RENIN RELEASE; RESTLESSNESS; REVIEW; REYNOLDS DISEASE; RHINITIS; SINUSITIS; SODIUM RETENTION; SUBARACHNOID HEMORRHAGE; SYSTOLIC HEART FAILURE; TERATOGENICITY; THORAX PAIN; VASOCONSTRICTION; VASODILATATION;

ANIMALS; CARDIOVASCULAR AGENTS; CHRONIC DISEASE; CYTOKINES; HEART FAILURE; HORMONE ANTAGONISTS; HUMANS; NEPRILYSIN; NEUROSECRETORY SYSTEMS; PROTEASE INHIBITORS; RECEPTORS, ENDOTHELIN; RECEPTORS, VASOPRESSIN; RENIN-ANGIOTENSIN SYSTEM; TREATMENT OUTCOME;

EID: 79956314908     PISSN: 00016837     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (44)

1. Kusumoto F.: in Pathophysiology of disease. An introduction to clinical medicine. Fourth edition., McPhee S.J., Lingappa V.R., Ganong W.F. Eds., p. 260, Lange Medical Books/McGraw-Hill, New York 2003.
2. Cardiovascular system. In: Handbook of pathophysiology. 2nd edn., Merkle C.J. Ed., p. 135, Lippincott Williams & Wilkins/A Wolters Kluwer Company, Philadelphia 2005.
3. Ramani G.V., Uber P.A., Mehra M.R.: Mayo Clin. Proc. 85, 180 (2010).
4. Kjaer A., Hesse B.: Clin. Physiol. 21, 661 (2001).
5. Zaman M.A., Oparil S., Calhoun D.A.: Nat. Rev. Drug Discov. 1, 621 (2002)
6. Brewster U.C., Parazella M.A.: Am. J. Med. 116, 263 (2004).
7. Perazella M.A., Setaro J.F.: J. Nucl. Cardiol. 10, 184 (2003).
8. Stanton A.: J. Renin Angiotensin Aldosterone Syst. 4, 6 (2003).
9. Fabiani M.E., Johnston C.I.: Curr. Hypertens. Rep. 1, 394 (1999).
10. Sablik Z., Drożdż J.: Terapia 1, 35 (2010). (Polish).
11. Różycka-Kosmalska M., Drożdż J.: Terapia 1, 45 (2010). (Polish).
12. Łuczak K., Drożdż J.: Terapia 1, 53 (2010). (Polish).
13. Unger T., Li .J: J. Renin Angiotensin Aldosterone Syst. 5 (Suppl. 1), S7 (2004).
14. Swedberg K.: J. Renin Angiotensin Aldosterone Syst. 5 (Supp. 1), S34 (2004).
15. Metra M., Nodari S., Dei Cas L.: J. Renin Angiotensin Aldosterone Syst. 5 (Suppl. 1), S11 (2004).
16. Struthers A.D.: J. Renin Angiotensin Aldosterone Syst. 5 (Suppl. 1), S23 (2004).
17. McMurray J.: J. Renin Angiotensin Aldosterone Syst. 5 (Suppl. 1), S17 (2004).
18. Ali F., Guglin M., Vaitkevicius P., Ghali J.K.: Drugs 67, 847 (2007).
19. Greenberg A., Verbalis J.G.: Kidney Int. 69, 2124 (2006).
20. Olszewski W., Głuszek J.: Pol. Arch. Med. Wewn. 8, 356 (2007). (Polish).
21. Decaux G., Soupart A., Vassart G.: Lancet 371, 1624 (2008).
22. Lemmens-Gruber R., Kamyar M.: Cell. Mol. Life Sci. 63, 1766 (2006).
23. Dobrek Ł., Thor P.: Farm. Przegl. Nauk. 11, 15 (2009). (Polish).
24. Han B., Hasin Y.: Cardiovasc. Drugs Ther. 17, 41 (2003).
25. Yap L.B.: Heart Fail. Rev. 9, 99 (2004).
26. Sharp A., Mayet J.: J. Renin Angiotensin Aldosterone Syst. 5, 53 (2004).
27. Sagnella G.A.: J. Renin Angiotensin Aldosterone Syst. 1, 304 (2000).
28. Grabowski M., Orłowska-Baranowska E.: Folia Cardiol. 10, 431 (2003)
29. Sagnella G.A.: J. Renin Angiotensin Aldosterone Syst. 3, 90 (2002).
30. Dawson A., Struthers A.D.: J. Renin Angiotensin Aldosterone Syst. 3, 156 (2002).
31. Dobrek Ł., Thor P.: Farm. Przegl. Nauk. 1, 31 (2010). (Polish).
32. Tabrizchi R.: Drugs 63, 2185 (2003).
33. Miyauchi T., Masaki T.: Annu. Rev. Physiol. 61, 391 (1999).
34. Motte S., McEntee K., Naeije R.: Pharmacol. Ther. 110, 386 (2006).
35. Tostes R.C.A., Muscara M.N.: Curr. Drug. Targets Cardiovasc. Haematol. Disord. 5, 287 (2005).
36. Ertl G., Bauersachs J.: Drugs 64, 1029 (2004).
37. Suresh D.P., Lamba S., Abraham W.T.: J. Card. Fail. 6, 359 (2000).
38. Feldman A.M., Combes A., Wagner D., Kadakomi T., Kubota T., Li Y.Y., McTiernan C.: J. Am. Coll. Cardiol. 35, 537 (2000)
39. Parissis J.T., Venetsanou K.F., Mentzikof D.G., Ziras N.G., Kefalas C.G., Karas S.M.: Scand. Cardiovasc. J. 33, 344 (1999).
40. Torre-Amione G., Kapadia S., Benedict C., Oral H., Young J.B., Mann D.L.: J. Am. Coll. Cardiol. 27, 1201 (1996).
41. Bozkurt B., Kribbs S.B., Clubb F.J., Michael L.H., Didenko V.V., Hornsby P.J., Seta Y., et al.: Circulation 97, 1382 (1998).
42. Rauchhaus M., Doehner W., Francis D.P., Davos C., Kemp M., Liebenthal C., Niebauer J., et al.: Circulation 102, 3060 (2000).
43. Mann D.J., McMurray J.J.V., Packer M., Swedberg K., Borer J.S., Colucci W.S., Djian J., et al.: Circulation 109, 76 (2004).
44. A service of the U.S. National Institutes of Health http:// clinicaltrials.gov/.